In vitro antimicrobial activity of ritipenem acoxil, a new oral penem, and its therapeutic efficacy in respiratory infections

M. Tateyama, H. Fukuhara, J. Inadome, M. Gaja, A. Saito, Nobuchika Kusano, F. Furugen, I. Nakasone, S. Taira, Y. Irabu, T. Oyakawa, M. Miyagi, I. Gakiya

Research output: Contribution to journalArticle

Abstract

We performed a basic evaluation of ritipenem acoxil (RIPM-AC), a newly developed oral penem, and clinically studied its application in the treatment of respiratory infections, with the following results. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of ritipenem (RIPM) for a total of 296 strains of 13 clinically isolated species were measured and compared with those of cefaclor (CCL), cefotiam (CTM), cefixime (CFIX), cefteram (CFTM) and amoxicillin (AMPC). The activity of RIPM against gram- positive bacteria was nearly equal to that of AMPC, and thus more active than that of other antibiotics. Against gram-negative bacteria, its activity was similar to that of the other antibiotics. 2) Clinical efficacy. RIPM-AC was administered to 8 patients with respiratory infections (acute bronchitis 4, acute exacerbation of chronic bronchitis 2, pneumonia 2) at 150-400 mg t.i.d. for 6-14 days. The clinical efficacy was excellent in 1 case, good in 5 cases, fair in 1 case and was not evaluated in 1 case. Causative bacteria were Haemophilus influenzae (1) and Enterobacter cloacae (1). Both of 2 strains were eradicated. No side effects were observed in any patient. As abnormal laboratory findings, eosinophilia in 1 case and elevations of s-Cr. GOT and GPT in 1 case were observed, but they were mild and transient.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 3
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

meropenem
Respiratory Tract Infections
Cefotiam
Cefixime
Cefaclor
Anti-Bacterial Agents
Enterobacter cloacae
Bronchitis
Chronic Bronchitis
Amoxicillin
Haemophilus influenzae
Eosinophilia
Gram-Positive Bacteria
Microbial Sensitivity Tests
Therapeutics
Gram-Negative Bacteria
Pneumonia
Bacteria
ritipenem
In Vitro Techniques

Keywords

  • ritipenem acoxil

ASJC Scopus subject areas

  • Pharmacology

Cite this

In vitro antimicrobial activity of ritipenem acoxil, a new oral penem, and its therapeutic efficacy in respiratory infections. / Tateyama, M.; Fukuhara, H.; Inadome, J.; Gaja, M.; Saito, A.; Kusano, Nobuchika; Furugen, F.; Nakasone, I.; Taira, S.; Irabu, Y.; Oyakawa, T.; Miyagi, M.; Gakiya, I.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 3, 1995, p. 193-199.

Research output: Contribution to journalArticle

Tateyama, M, Fukuhara, H, Inadome, J, Gaja, M, Saito, A, Kusano, N, Furugen, F, Nakasone, I, Taira, S, Irabu, Y, Oyakawa, T, Miyagi, M & Gakiya, I 1995, 'In vitro antimicrobial activity of ritipenem acoxil, a new oral penem, and its therapeutic efficacy in respiratory infections', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 3, pp. 193-199.
Tateyama, M. ; Fukuhara, H. ; Inadome, J. ; Gaja, M. ; Saito, A. ; Kusano, Nobuchika ; Furugen, F. ; Nakasone, I. ; Taira, S. ; Irabu, Y. ; Oyakawa, T. ; Miyagi, M. ; Gakiya, I. / In vitro antimicrobial activity of ritipenem acoxil, a new oral penem, and its therapeutic efficacy in respiratory infections. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 3. pp. 193-199.
@article{11f247dd842d46d3b39032d0f2e414c2,
title = "In vitro antimicrobial activity of ritipenem acoxil, a new oral penem, and its therapeutic efficacy in respiratory infections",
abstract = "We performed a basic evaluation of ritipenem acoxil (RIPM-AC), a newly developed oral penem, and clinically studied its application in the treatment of respiratory infections, with the following results. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of ritipenem (RIPM) for a total of 296 strains of 13 clinically isolated species were measured and compared with those of cefaclor (CCL), cefotiam (CTM), cefixime (CFIX), cefteram (CFTM) and amoxicillin (AMPC). The activity of RIPM against gram- positive bacteria was nearly equal to that of AMPC, and thus more active than that of other antibiotics. Against gram-negative bacteria, its activity was similar to that of the other antibiotics. 2) Clinical efficacy. RIPM-AC was administered to 8 patients with respiratory infections (acute bronchitis 4, acute exacerbation of chronic bronchitis 2, pneumonia 2) at 150-400 mg t.i.d. for 6-14 days. The clinical efficacy was excellent in 1 case, good in 5 cases, fair in 1 case and was not evaluated in 1 case. Causative bacteria were Haemophilus influenzae (1) and Enterobacter cloacae (1). Both of 2 strains were eradicated. No side effects were observed in any patient. As abnormal laboratory findings, eosinophilia in 1 case and elevations of s-Cr. GOT and GPT in 1 case were observed, but they were mild and transient.",
keywords = "ritipenem acoxil",
author = "M. Tateyama and H. Fukuhara and J. Inadome and M. Gaja and A. Saito and Nobuchika Kusano and F. Furugen and I. Nakasone and S. Taira and Y. Irabu and T. Oyakawa and M. Miyagi and I. Gakiya",
year = "1995",
language = "English",
volume = "43",
pages = "193--199",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 3",

}

TY - JOUR

T1 - In vitro antimicrobial activity of ritipenem acoxil, a new oral penem, and its therapeutic efficacy in respiratory infections

AU - Tateyama, M.

AU - Fukuhara, H.

AU - Inadome, J.

AU - Gaja, M.

AU - Saito, A.

AU - Kusano, Nobuchika

AU - Furugen, F.

AU - Nakasone, I.

AU - Taira, S.

AU - Irabu, Y.

AU - Oyakawa, T.

AU - Miyagi, M.

AU - Gakiya, I.

PY - 1995

Y1 - 1995

N2 - We performed a basic evaluation of ritipenem acoxil (RIPM-AC), a newly developed oral penem, and clinically studied its application in the treatment of respiratory infections, with the following results. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of ritipenem (RIPM) for a total of 296 strains of 13 clinically isolated species were measured and compared with those of cefaclor (CCL), cefotiam (CTM), cefixime (CFIX), cefteram (CFTM) and amoxicillin (AMPC). The activity of RIPM against gram- positive bacteria was nearly equal to that of AMPC, and thus more active than that of other antibiotics. Against gram-negative bacteria, its activity was similar to that of the other antibiotics. 2) Clinical efficacy. RIPM-AC was administered to 8 patients with respiratory infections (acute bronchitis 4, acute exacerbation of chronic bronchitis 2, pneumonia 2) at 150-400 mg t.i.d. for 6-14 days. The clinical efficacy was excellent in 1 case, good in 5 cases, fair in 1 case and was not evaluated in 1 case. Causative bacteria were Haemophilus influenzae (1) and Enterobacter cloacae (1). Both of 2 strains were eradicated. No side effects were observed in any patient. As abnormal laboratory findings, eosinophilia in 1 case and elevations of s-Cr. GOT and GPT in 1 case were observed, but they were mild and transient.

AB - We performed a basic evaluation of ritipenem acoxil (RIPM-AC), a newly developed oral penem, and clinically studied its application in the treatment of respiratory infections, with the following results. 1) Laboratory activity. The minimum inhibitory concentrations (MICs) of ritipenem (RIPM) for a total of 296 strains of 13 clinically isolated species were measured and compared with those of cefaclor (CCL), cefotiam (CTM), cefixime (CFIX), cefteram (CFTM) and amoxicillin (AMPC). The activity of RIPM against gram- positive bacteria was nearly equal to that of AMPC, and thus more active than that of other antibiotics. Against gram-negative bacteria, its activity was similar to that of the other antibiotics. 2) Clinical efficacy. RIPM-AC was administered to 8 patients with respiratory infections (acute bronchitis 4, acute exacerbation of chronic bronchitis 2, pneumonia 2) at 150-400 mg t.i.d. for 6-14 days. The clinical efficacy was excellent in 1 case, good in 5 cases, fair in 1 case and was not evaluated in 1 case. Causative bacteria were Haemophilus influenzae (1) and Enterobacter cloacae (1). Both of 2 strains were eradicated. No side effects were observed in any patient. As abnormal laboratory findings, eosinophilia in 1 case and elevations of s-Cr. GOT and GPT in 1 case were observed, but they were mild and transient.

KW - ritipenem acoxil

UR - http://www.scopus.com/inward/record.url?scp=0028850580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028850580&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 193

EP - 199

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 3

ER -